Predictor of primary response to antitumor necrosis factor-α therapy for inflammatory bowel disease: a single-center observational study

Abstract

K else and the improvement of disease activity index was shown in Crohn's disease patients (univariate: estimated value 2.4; P = 0.003; and multivariate: 1.8; P = 0.012) and ulcerative colitis patients (univariate: 0.12; P = 0.011), and no other factors were significant. Conclusion This is the first study to present a useful predictor of primary response to anti-TNFα of individual IBD patients at second administration. The K anti-TNFα 0 /K else ratio may help to select the optimal therapeutic drug and avoid the improper continuous administration of anti-TNFα in the induction phase.

Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review

“…Pharmacokinetic/pharmacodynamic modeling: Kimura et al [ 69 ] developed Pharmacokinetic/pharmacodynamic (PK/PD) modeling to predict IBD response to infliximab during induction therapy. Another team of researchers in Japan developed a PK/PD model to calculate the K anti-TNFα 0 /K else ratio to predict the PNR to TNF in IBD patients at the second administration[ 70 ]. The validity of this model remains to be tested in larger populations.…”